Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05190315 · ClinicalTrials.gov registry record · Phase 1
Chlorpromazine and Standard of Care in Glioblastoma
A Phase 1 study, sponsored by Mohammed Milhem.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05190315 is a Phase 1 study that has completed, run by Mohammed Milhem. The registered enrollment target is 10 participants.
The verdict
NCT05190315, a Phase 1 study, has completed, sponsored by Mohammed Milhem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a phase 1 study investigating the re-purposing of chlorpromazine, combined with temozolomide and radiation in the treatment of newly diagnosed glioblastoma multiforme.
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DRUG Chlorpromazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2024-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05190315
The ClinicalTrials.gov registry entry for NCT05190315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mohammed Milhem, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT05190315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05190315 about?
NCT05190315 is a clinical study titled "Chlorpromazine and Standard of Care in Glioblastoma". This is a phase 1 study investigating the re-purposing of chlorpromazine, combined with temozolomide and radiation in the treatment of newly diagnosed glioblastoma multiforme.
What is the current status of trial NCT05190315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-01-28. Estimated completion is 2024-07-28.
What interventions are being tested in trial NCT05190315?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Chlorpromazine (DRUG).
Who is sponsoring clinical trial NCT05190315?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.